Introduction
Prolonged antithrombotic therapy reduces the risk of myocardial infarction, stroke and mortality in patients with documented vascular disease, using either aspirin [1, 2] , clopidogrel [3] , or coumadin [4, 5] . Aspirin and clopidogrel, which are relatively weak inhibitors of platelet aggregation, have demonstrated moderate levels of efficacy. Therefore it has been postulated that more potent platelet function inhibitors might be more effective as treatment and secondary prevention in selected patients with cardiovascular disease.
The glycoprotein GPIIb/IIIa receptor blockers inhibit the final common pathway of platelet aggregation. When given intravenously in an acute setting, these agents (abciximab, eptifibatide, tirofiban) significantly reduce thrombotic complications associated with percutaneous coronary intervention [6, 7] , particularly the risk of procedure-related myocardial infarction. This risk reduction was achieved in patients with stable or unstable angina or myocardial infarction following both balloon angioplasty and placement of stents [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Preliminary data from the recent TARGET study showed a significantly better efficacy of treatment with abciximab than with tirofiban for the dose regimens used in patients undergoing percutaneous coronary intervention [18] . Furthermore, GPIIb/IIIa receptor blockers reduce the risk of progression to (re)infarction or death in patients with acute coronary syndromes, whether treated medically, or with coronary revascularization [9, 17, [19] [20] [21] [22] . Yet the GUSTO IV-ACS study did not confirm a benefit of medical treatment with abciximab in patients who did not undergo early coronary revascularization [23] . Based on the success of short-term intravenous administration of GPIIb/IIIa inhibitors in preventing thrombotic complications after percutaneous coronary intervention and in patients with acute coronary syndromes, oral GPIIb/IIIa receptor inhibitors have been developed for chronic use in patients at high risk of arterial thrombotic events, including prolonged treatment and secondary prevention after acute coronary syndromes. During the last few years at least 10 drugs have entered clinical development and a few are currently in development or were recently evaluated in phase II or III clinical studies. However, to the surprise of many investigators, the first large clinical trials with oral GPIIb/IIIa receptor blockers yielded a neutral or slightly negative result with a small but significant excess in mortality in patients receiving oral GPIIb/IIIa receptor blockers. Therefore, under the auspices of the European Society of Cardiology, a meeting was convened in London on 4 and 5 May, 2000 to review the trial results and to discuss possible explanations for the adverse drug effects. The key points of the discussion among representatives from academia and industry are summarized in this report. The participants are listed in the appendix.
Pharmacology and pharmacokinetics
The oral GPIIb/IIIa receptor blockers are all highly selective for the GPIIb/IIIa receptor, and thereby inhibit the final common pathway of platelet aggregation. The drugs have in common an RGD-site or RGD-like site that binds to the RGD-binding site of the GPIIb/IIIa receptor on platelets [24] . An overview of these drugs is given in Table 1 . The various oral GPIIb/IIIa antagonists differ in their pharmacodynamic and pharmacokinetic profile, as has recently been reviewed by Verstraete [25] . All act rapidly, although some are prodrugs that have to be processed *Active drug. **For the parent compound using TRAP-activated platelets. ***For the parent compound using unactivated platelets.
first to an active drug. Lotrafiban and klerval are administered as active drugs; the metabolite of the latter is also active. The bioavailability of all oral agents after ingestion is low and ranges from 2·3% to 38%. Most drugs have a high affinity to the receptor, although the affinities for resting and activated platelets does differ among the various drugs. Nearly all drugs have a short biological half-life and are dosed two or three times daily, resulting in relatively high peak and low trough levels, or a high peak/trough ratio. It has been suggested that the best oral agent might be a drug with a long half-life and a low peak/trough ratio, so that a stable platelet inhibitory effect is obtained over time. One of the drugs with such a pharmacological profile is roxifiban. This drug has a long half-life and a high affinity for resting and activated platelets along with a slow dissociation rate, suggesting a possible prolonged duration of in vivo antiplatelet effect if given daily. However, the slow dissociation rate may not be desirable from the safety perspective for a chronic oral agent. The optimal profile for chronic therapy has yet to be defined and efficacy of the various oral agents may differ by indication.
Clinical trials
To date, several phase II trials and five large randomized phase III trials have been conducted evaluating the efficacy and safety of oral GPIIb/IIIa inhibitors in several clinical settings. A brief summary of the phase III trials characteristics is presented in Table 2 . Tables  3 and 4 present the main efficacy and safety outcome results, respectively. The trials differ in end-points, target populations, pharmacodynamic profiles, and dosing with or without aspirin. The trials are not directly comparable and the results of a collective analysis must be put into perspective. The phase II studies included 2013 patients receiving either placebo or different doses of the various agents. The primary end-points (death, myocardial infarction, recurrent ischaemia, or stroke) suggested a modest treatment benefit (odds ratio 0·85; 0·65-1·11). However, lefradafiban in FROST demonstrated a higher incidence of death or the composite end-point of death or myocardial infarction in the treatment groups as compared to placebo. Sibrafiban, xemilofiban and lotrafiban demonstrated a higher incidence of death or myocardial infarction in the highest dose groups as well. As expected bleeding was increased, but only one patient developed intracranial haemorrhage while also receiving thrombolytic therapy (Table 4) . Based on these phase II results, industry and investigators expected an overall treatment benefit, with a modest and acceptable level of bleeding complications. In the Evaluation of oral Xemilofiban in Controlling Thrombotic Events (EXCITE) trial 7232 patients were randomly assigned to receive 20 mg of oral xemilofiban or placebo 30 to 90 min before undergoing percutaneous coronary intervention, with maintenance doses of 10 or 20 mg of xemilofiban or placebo administered three times daily for up to 182 days [26] . The primary efficacy end-point (a composite of death, myocardial infarction and urgent revascularization within 6 months) occurred in 13·4% of patients randomized to placebo, and in 13·8% and 12·7% of those receiving low and high dose xemilofiban, respectively. The incidence of death or myocardial infarction was also similar in all three groups. There was a slight, but significant excess mortality at 6 months follow-up in the low-dose xemilofiban treatment arm as compared to placebo (1·7% and 1·0%, respectively; P=0·04). Major bleeding complications occurred in 4·4%-6·0% of patients randomized to xemilofiban, compared with 1·6% in placebo (P<0·001 for both comparisons). Intracranial haemorrhages were rare, but also more frequent after xemilofiban.
The Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial randomized 10 288 patients with acute coronary syndromes (not necessary stabilized) within 72 h to receive either 50 mg orbofiban twice daily (50/50 group), 50 mg orbofiban twice daily for 30 days followed by 30 mg orbofiban twice daily (50/30 group), or placebo [27] . Treatment and follow-up were planned to continue for an average of 1 year (minimum of 6 months for each patient), but the trial was terminated prematurely because of an excess mortality in the 50/30 orbofiban group. Again in OPUS-TIMI 16 there was no difference in the primary efficacy end-point at an average of 10 months follow-up. The incidence of mortality and the composite incidence of mortality and non-fatal myocardial infarction were higher in patients randomized to one of the orbofiban arms than placebo; however, this was during the first 30 days after randomization when the dose received was the same in the two patient groups. In retrospect, the group with the increased mortality included patients with Class IV heart failure and renal insufficiency. Also major bleeding complications were more frequent with orbofiban (2·0% in placebo, 3·7% in the 50/30 orbofiban treatment arm and 4·5% in 50/50 orbofiban) at 10 months.
The first Sibrafiban versus Aspirin to Yield Maximum Protection from Ischaemic Heart Events Postacute Coronary Syndromes (SYMPHONY) trial The results of the recently interrupted BRAVO trial (lotrafiban in acute coronary syndromes, stroke or transient ischaemic attack) are not available yet.
Table 3 Thrombotic events in Phase II and III trials on oral GPIIb/IIIa blockers
Acronym study randomized 9233 patients who had stabilized after an acute coronary syndrome to 90-day treatment with either aspirin (80 mg orally twice daily), or one of two dosages of oral sibrafiban [28] . The sibrafiban dose was either targeted to achieve a steady-state inhibition of platelet aggregation above 25% (low dose) or a higher level of platelet aggregation inhibition consistent with patient safety. The 90-day incidence of death, nonfatal myocardial infarction or recurrent ischaemia was similar in the three treatment arms. There was a slight, non-significant increase in the incidence of death or myocardial infarction in both sibrafiban groups compared to aspirin (7·9% in high-dose sibrafiban vs 7·0% in aspirin; OR and 95% CI 1·15 [0·95-1·39]). Major bleeding was significantly more common with sibrafiban than with aspirin. The incidence of intracranial haemorrhage was also higher (3 to 5 times) with sibrafiban (one patient vs four patients vs two patients; 0·03% vs 0·13% vs 0·07%), but statistical significance was not reached.
The second Sibrafiban versus Aspirin to Yield Maximum Protection from Ischaemic Heart Events Post-acute Coronary Syndromes (2nd SYMPHONY) trial evaluated the efficacy of combination therapy with aspirin and low-dose sibrafiban versus aspirin or high-dose sibrafiban alone in acute coronary syndrome patients [29] . 2nd SYMPHONY was designed to randomize as many as 8400 patients, but was terminated after the enrolment of 6637 patients because of the negative results of the first SYM-PHONY. The study regimens of SYMPHONY-2 were similar to SYMPHONY-1, except that patients in the sibrafiban low-dose group also received aspirin. The 90-day primary efficacy end-point of death, nonfatal myocardial infarction or recurrent ischaemia was more frequent in patients randomized to highdose sibrafiban (10·5%) than placebo (9·3%) and low-dose sibrafiban (9·2%), but statistical significance was not reached. Death and the composite of death or non-fatal myocardial infarction was significantly more frequent at 90-day follow-up with high-dose sibrafiban than with placebo (OR and 95% CI for death 1·86 [1·18-2·94], and for death or myocardial infarction 1·45 [1·15-1 82]). Again, the long-term use of sibrafiban was associated with an increased incidence of bleeding complications.
The BRAVO trial was ongoing at the time of the colloquium, and was stopped in December 2000. The Data Safety Monitoring Board recommended termination of the trial because of excess mortality at interim analysis (2·7% lotrafiban vs 2·0% placebo, P=0·022) with more serious thrombocytopenia (2·2% vs 0·5%) and an excess of major bleeding complications (4·2% vs 1·3%, P<0·0001) (data obtained from Heartwire;www.theheart.org, 12 December, 2000).
The preliminary results are based on data entered in a database. Data collection will be completed and final results are expected soon.
The four reported phase III clinical trials with oral GPIIb/IIIa inhibitors randomized almost 33 000 patients (22 000 were randomized to receive a GPIIb/ IIIa inhibitor and 11 000 placebo/aspirin). The longterm use of oral GPIIb/IIIa inhibitors did not reduce the incidence of cardiac complications in patients assumed to benefit from such therapy. Quite the contrary: an overall 31% increase was observed in the incidence of death (2·7% vs 2·1% in placebo; OR and 95% confidence interval (CI) 1·31 [1·31-1·53]) and a 13% increase in the incidence of either death or non-fatal myocardial infarction (8·4% vs 7·5%). Furthermore, long-term use of oral GPIIb/IIIa inhibitors was associated with a two-fold increase in the risk of (major) bleeding complications, and an increased risk of intracranial haemorrhage. The BRAVO preliminary results are concordant with these findings.
Discussion
In spite of the positive results of trials with short-term intravenous GPIIb/IIIa receptor blockade in patients with acute coronary syndromes and in patients undergoing coronary intervention, no additional benefit was observed with prolonged oral administration of similar agents after percutaneous coronary intervention [26] or after an episode of unstable angina or myocardial infarction [27] [28] [29] . The compiled data even show a slight but statistically significant increase in thrombotic complications (death and myocardial infarction) and particularly an increase in mortality in patients receiving xemilofiban, orbofiban or sibrafiban, while preliminary results with lotrafiban are similar. Several suggestions have been put forward which may explain these observations, including the target level of inhibition of platelet function, platelet activation, thrombin generation and patient selection.
Target level of inhibition platelet function
Early studies in animal models of arterial thrombosis with inhibitory antibodies directed towards the GPIIb/IIIa receptor by Coller et al. showed that maximal therapeutic benefit in preventing reocclusion was reached with a dosage that resulted in at least 80% inhibition of platelet aggregation using 20  adenosine diphosphate (ADP) in a turbiometric aggregometry assay [30] . The selected dose of abciximab to achieve this level of platelet function inhibition was shown to be effective in the first clinical studies in patients undergoing high risk coronary artery angioplasty or atherectomy [8, 10, 16] . Since then it is generally accepted that 80% inhibition in aggregometry studies using ADP is necessary to obtain optimal clinical benefit. This has also been demonstrated with other GPIIb/ IIIa antagonists, such as eptifibatide. Studies using a low dose of eptifibatide as given in the IMPACT II trial showed little benefit. The PURSUIT study improved upon the dosing and demonstrated benefit in this patient population. The ESPRIT trial using higher doses of eptifibatide in the percutaneous coronary intervention study, resulted in 90-95% platelet inhibition and showed a significant benefit [13, 14] . Recently this concept was confirmed in an observational study in 469 patients treated with abciximab, tirofiban or eptifibatide during percutaneous coronary intervention demonstrating a very low rate of thrombosis complications in patients with >70% platelet inhibition measured 8 h after the procedure, compared to a threefold increase in major adverse cardiac events in patients with less intense inhibition [31] . Theoretically a high level of platelet function inhibition is also desired with long-term oral GPIIb/IIIa receptor blockers. However, in patients receiving oral agents at high dosages for several months, the high level of GPIIb/IIIa inhibition leads to unacceptable bleeding complications, as has been reported in several phase II trials [32, 33] . For instance in the APLAUD (antiplatelet useful dose trial) study lotrafiban was dosed twice daily in different dosages and compared to placebo both on top of 325 mg aspirin. Lotrafiban was well tolerated at the lower doses but minor bleeding occurred in up to 70% of the patients in the highest dose (100 mg twice daily) group, particularly notable in the elderly and/or those with renal impairment. Major bleeding, defined as intracranial bleeding, or bleeding requiring transfusion or hospitalization occurred in 11·8% [32] . This high dose of lotrafiban resulted in a peak and trough level of ADP-induced platelet aggregation inhibition of 98% and 80%, respectively. A direct relationship between both dosage, drug level and % inhibition was shown for sibrafiban [34] as well as xemilofibran in the ORBIT trial [35] . In most phase II studies, however, the level of ADP aggregation inhibition was considerably less than 80%. In patients receiving a dose of 20 mg xemilofiban the % inhibition of mean ADPinduced platelet aggregation ranged from 51-87%. A maximum effect was seen 4 h after ingestion (73-87%). After 8 h platelet inhibition was less extensive (51-58% inhibition) [35] . Similar peak and trough levels of inhibition have been seen with sibrafiban, orbofiban and lotrafiban [27, 32, 34] .
Giugliano et al. reported the findings of the first study that combined intravenous and oral GPIIb/IIIa antagonists. After i.v. GPIIb/IIIa inhibitors for 24-96 h klerval was given orally for 4 weeks in a dose ranging from 350-600 mg twice or thrice daily. The oral drug gave a peak aggregation inhibition level of 40-60% and a pre-dose (nadir) level of around 20%, using ADP 20  as an antagonist in a turbodometric aggregation assay. In this study, despite a wide range of dosages of sustained oral GPIIb/IIIa blockade, platelet function was not inhibited more than 50% by klerval [36] . Thus, the level of inhibition targeted by oral agents may be too low to achieve benefit or at least achieves less benefit than obtained by i.v. agents at current dosages.
In all studies the administration of oral GPIIb/IIIa inhibitors resulted in a cyclic pattern of platelet inhibition. This may result in a higher risk of bleeding soon after ingestion of the drugs due to the high level of platelet function inhibition, and an increased risk of thrombotic complications just before the next dose is given.
Reviewing these data it has become apparent that: v High levels of platelet inhibition, as in short-term intravenous treatment, cannot be tolerated in longterm oral therapy since bleeding rates are excessive. v The variation in the level of inhibition in the agents tested so far at the intermediate level of platelet inhibition are significant. This may lead to bleeding (when platelet inhibition is more intense) or thrombotic complications (when platelet inhibition is low).
Platelet activation caused by GPIIb/IIIa inhibitors
Low plasma drug levels may also lead to paradoxical pro-thrombotic effects caused by platelet activation. Peter et al. [37] have shown in vitro that some GPIIb/ IIIa inhibitors have the ability to induce fibrinogen binding and platelet aggregation. This was based on the observation that ligand (fibrinogen) binding or binding of the ligand-mimetic peptide RGD, induces a conformational change in the GPIIb/IIIa receptor from a non-activated to an activated state. In this study, abciximab and fradafiban (the active form of the oral prodrug lefradafiban) were added to platelets and then removed by washing. This was shown to induce platelet aggregation at low concentrations of the drugs. The relevance of this intrinsic property of GPIIb/IIIa inhibitors is unknown and the clinical implications of these in vitro results to the in vivo situation are still unclear. Because oral drugs are targeted at lower levels of platelet function inhibition
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than with intravenous dosing, this paradoxical phenomenon of platelet aggregation may especially be of importance with oral GPIIb/IIIa use. It is suggested that aspirin could block the platelet aggregation induced by GPIIb/IIIa inhibitors [37] ; however, the results of studies that combine the two drugs are similar to the SYMPHONY trial in which no aspirin was given [28] . Platelet reactivity, known to be increased in patients with acute coronary syndromes, was determined in a substudy of the OPUS-TIMI 16 trial before randomization and after giving orbofiban or placebo combined with aspirin [38] . In patients receiving orbofiban, significant increased platelet reactivity with respect to fibrinogen binding and P-selectin expression was found after 14 days of treatment. In placebo-treated patients (only receiving aspirin) decreased platelet reactivity was found. It has been suggested that this may be related to conformational changes of the GPIIb/IIIa receptor upon binding of the drug. This may result in the receptor having increased affinity for fibrinogen, as has also been reported in the study of Peter et al. [37, 38] . This phenomenon of platelet activation was especially seen at low dosage of orbofiban. In a recent study by Cox et al. it was demonstrated that surface CD63 expression, a marker of lysosome release, which occurs if resting platelets are becoming activated, is increased during treatment with orbofiban [39] . This group also showed that orbofiban led to increased thromboxane A 2 release in vitro, a second measure of platelet activation [40] . These results suggest that certain GPIIb/IIIa antagonists may act as a partial agonist. Higher receptor occupancy by increased dosing may prevent this phenomenon with those drugs that appear to have the property of 'partial agonist'. It is not clear whether these results explain the outcome of the clinical trials or if such experiments would be predictive of clinical outcome for newly developed agents.
An interesting and important phenomenon was seen in the FROST study, in which lefradafiban was given as an oral GPIIb/IIIa inhibitor in patients with acute coronary syndromes [33] . Based on measured plasma drug concentrations and the calculated ADPinduced platelet aggregation inhibition level, it was shown that a high level of ADP-induced platelet aggregation inhibition resulted in a markedly reduced incidence of combined end-points, such as death, myocardial infarction or recurrent angina pectoris. However, at a platelet aggregation inhibition level of 30-50% an increase in thrombotic end-points was seen (Fig. 1) . This increased number of events may be explained by platelet activation found at lower levels of GPIIb/IIIa inhibitor levels, as discussed above.
These data suggest that low levels of GPIIb/IIIa blockade may result in platelet activation and paradoxically increased incidence of thrombotic events.
Thrombin generation and the use of GPIIb/IIIa inhibitors
Several studies have shown an important link between platelet aggregation and subsequent thrombin formation. Inhibition of platelet function also results in inhibition of the coagulation pathway. Abciximab is able to reduce platelet-mediated, tissue factorinduced thrombin generation in vitro. This effect of abciximab is partly due to inhibition of the GPIIb/ IIIa receptor, but also partly due to inhibition of the vitronectin receptor [41] . In patients with unstable coronary syndromes undergoing percutaneous coronary intervention, the addition of abciximab to aspirin and heparin during percutaneous coronary intervention was associated with a significant decrease in thrombin generation [42] . The effect on platelet-mediated thrombin generation in patients treated with oral GPIIb/IIIa inhibitors, for instance by measuring thrombin-antithrombin complexes, has not been studied extensively. The observation that platelet reactivity is increased in patients treated with orbofiban, as mentioned above, may theoretically indicate that thrombin generation is increased and may be an additional explanation for the disappointing results of the trials with oral GPIIb/ IIIa inhibitors. This hypothesis is strengthened by the finding in the OPUS-TIMI 16 study, that patients [33] . Each open dot represents the mean % of end-points observed in a 25% range of platelet aggregation inhibition as indicated by the horizontal line. The line at 16·9% of end-points represents the frequency in the placebo 'treated' patient group. receiving unfractionated or low molecular weight heparin during the first 2 days had a significantly lower 30 day mortality compared to patients receiving no heparin [27] . Similar findings have been observed with i.v. GPIIb/IIIa blocker, where results are more beneficial with concomitant heparin than without [17, 19, 20] .
Methods that are used to determine platelet function
An important issue for the evaluation of all phase II and III studies is the difference in methods that are used to study platelet function inhibition by oral and intravenous GPIIb/IIIa inhibitors. As mentioned before, the first (animal) studies showed that the efficacy of GPIIb/IIIa inhibitors is strongly dependent upon the amount of inhibition that is reached. Coller et al. [30] have shown that >80% inhibition of ADPinduced platelet aggregation is necessary for clinical benefit. Since then, all studies with intravenous administration of GPIIb/IIIa inhibitors have aimed for the same level of platelet function inhibition. However, platelet aggregation is a function of the agonist used (ADP, TRAP, or other), agonist concentration, assay conditions, and equipment/technology employed. Also the results may be influenced by the way the aggregation curve is interpreted, i.e. the maximal extent or the slope of the curve.
In addition, the results may be influenced by the collection medium used. Some GPIIb/IIIa antagonists such as eptifibatide show higher levels of platelet function inhibition in citrate anticoagulated blood compared to PPACK (thrombin inhibitor) [43] . This is caused by the lower ionized calcium concentrations in citrate blood, which makes the platelets more susceptible to inhibition by GPIIb/IIIa antagonists when challenged with platelet agonists. The use of PPACK as a standard anticoagulant may provide more accurate assessment of platelet function inhibition [43, 44] . For these reasons, it remains very difficult to determine how reliable is the measured in vitro effect in the in vivo situation.
The relationship between clinical outcome in patients treated with GPIIb/IIIa inhibitors and the extent of platelet inhibition is not completely clear in the many studies performed [45] ; however, aggregation studies using 20  ADP are the 'gold standard' for measuring platelet function in these patients.
Several other platelet function assays have been used to study the effect of GPIIb/IIIa inhibitors. The most direct way of measuring the extent of GPIIb/ IIIa inhibition is to measure the fibrinogen binding capacity of platelets. Most of the methods use flow cytometry with labelled fibrinogen or other ligands. These methods are very time-consuming, require skilled technicians and are not available in every laboratory. Coller et al. [46] have developed a bedside device to assess platelet function based on the ability of activated platelets (induced by isoTRAP) to bind to fibrinogen. This test (Rapid Platelet Function Analyser, RPFA, Accumetrics, U.S.A.) shows a very good correlation with both receptor occupancy and the ADP platelet aggregation assay and is in use to monitor intravenously given GPIIb/IIIa antagonists [47] . In a recent study using RPFA in patients receiving various intravenous GPIIb/IIIa antagonists during percutaneous coronary intervention, wide variability in platelet function inhibition was found, despite fixed dosages of GPIIb/IIIa blockers. Inhibition of >70% measured at 8 h by RPFA was significantly related to improved clinical outcome compared with lower levels of inhibition [31] . Other tests for measuring primary platelet function inhibition are currently under investigation and may also have a potential role in establishing platelet function in the future [48] . The outcome of these tests has not yet been related to clinical outcome. In conclusion, the techniques to monitor GPIIb/IIIa receptor blockers in vitro, to assess platelet function in vivo, are not optimized. More studies are required to relate new assays to clinical end-points, such as thrombotic events and bleeding episodes.
Patient selection
In patients undergoing percutaneous coronary intervention, procedure-related myocardial infarction, as assessed by myocardial protein release, occurs in approximately 10% of patients. Part of such damage is related to rupture of the plaque or disruption of the vascular wall by the procedure, resulting in local thrombosis with distal embolization. Indeed, antiplatelet therapy with intravenous glycoprotein GPIIb/IIIa receptor blockers markedly reduces this risk [7] [8] [9] [10] [11] [12] [13] [14] . In trials with oral GPIIb/IIIa receptor blockers a similar although smaller peri-procedural risk reduction has been observed with xemilofiban and orbofiban [26, 27] . These clinical observations support the efficacy of oral GPIIb/IIIa receptor blockers, albeit at a lower level of platelet inhibition than achieved with the intravenous agents. During follow-up after a percutaneous coronary intervention procedure, new thrombotic events are rare, for example in EXCITE most events occurred within one day of randomization [26] . In most patients the clinical course is uncompromised once the procedure has been completed. Accordingly, in these patients there
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is little room for improvement by continuation of an oral GPIIb/IIIa receptor blocker. Procedure-related myocardial infarction is most frequent in patients with unstable angina, particularly if troponin levels are elevated before the procedure [9] . However, in such patients the situation becomes stable once the procedure has been completed. It seems unlikely therefore that long-term treatment with a GPIIb/IIIa receptor blocker will be appropriate after a percutaneous coronary intervention procedure, particularly in view of the associated bleeding risk.
In patients with acute coronary syndromes who do not undergo a coronary revascularization procedure, events (myocardial infarction) continue to occur during the first few months. In such patients, continuation of intensive antithrombotic therapy may be appropriate, particularly if cardiac troponin levels are elevated at enrolment. In the clinical trials conducted with oral GPIIb/IIIa receptor blockers, many patients underwent an early coronary revascularization procedure. One trial (EXCITE) specifically investigated patient post percutaneous coronary intervention [26] . Cardiac troponin levels were not measured and many patients may have been troponin negative, and accordingly at low risk for recurrent events.
Another patient-associated factor in GPIIb/IIIa inhibitors may be the relationship of polymorphisms in the gene encoding for the GPIIb/IIIa receptor and the occurrence of cardiovascular disease. Previous studies have shown an association between a GPIIb/ IIIa polymorphism PlA2 and acute coronary thrombosis [49] , although this has been debated by others [50] . It has also been suggested that patients with the PlA2 allelle will have an increased risk of coronary stent thrombosis [51] . Recently, the effect of the PlA2 polymorphism on the outcome of GPIIb/IIIa inhibitor treatment has been evaluated in patients receiving orbofiban in a substudy of the OPUS-TIMI-16 trial. This study showed that the polymorphism PlA2 was associated with increased cardiac events, and conversely that patients with a normal GPIIb/IIIa receptor had trends towards benefit of orbofiban on cardiac events. This suggests that patients with the PlA2 polymorphism, who have an abnormal receptor, may not respond to this class of agents. However, further studies are needed before definite recommendations can be given.
Future directions for clinical trials
The five large phase III studies with xemilofiban, orbofiban, sibrafiban and lotrafiban have been conducted with limited phase II experience. It has been argued that larger phase II studies would not be useful in this clinical setting since it will not be possible to achieve a reasonable estimate of the expected clinical benefit. On the other hand, larger phase II studies might have allowed a more careful assessment of the pharmacology, pharmacokinetics and pharmacodynamics of the agents involved. If future studies with these and similar agents are considered, in spite of the consistent negative findings in more than 40 000 patients (including BRAVO), the need for more detailed and larger phase II studies should carefully be reassessed.
Some investigators suggest, based on the increase in mortality, that studies with (other) GPIIb/IIIa blockers should cease immediately [52] . However, we think that additional investigators on oral GPIIb/IIIa blockers could be considered under specific conditions. Patient groups should clearly be defined, for instance patients with high risk acute coronary syndromes and elevated troponin. In smaller studies, subgroups of patients should be identified who have a higher expected benefit of treatment. Drugs with a long half-life and little variation in blood levels should be used. Also individual monitoring of patients with respect to platelet function inhibition is necessary to establish the optimal target level of inhibition. All these factors have to be taken into account before further large scale phase III studies are initiated.
Conclusions
Several possible explanations have been postulated for the failure of oral GPIIb/IIIa inhibitors: high levels of inhibition, as reached with the intravenous drugs, are not tolerable for chronic use because of excess bleeding. Low levels of inhibition seem to be insufficient to reduce recurrent thrombotic events, and may even, by inducing platelet activation and thrombin generation, result in an increased risk of thrombotic events. It is important to note the differences in pharmacokinetic profiles of the different agents, since these may be strongly related to outcome. Perhaps the use of new drugs currently in development with more stable levels of inhibition may result in more favourable clinical outcome; however, this has to be proven in clinical studies.
Patient-related factors also may play a role, such as the selection of (low-risk) patients or the presence of PlA2 polymorphism in the GPIIb/IIIa receptor.
Methods for monitoring of the different drugs should be fully investigated and improved. Several assays are in use, however only limited studies have been performed to validate these assays in relation to clinical outcome.
The future might include a search for oral drugs with more stable levels of inhibition and a high affinity to the GPIIb/IIIa receptor. Appropriately sized phase II clinical studies should focus on high risk patients before large-scale studies are performed. Monitoring of GPIIb/IIIa receptor blockers treatment should be optimized and related to clinical outcome. In view of the consistently negative results so far, strong arguments must be presented to continue this development, and the validity of such arguments must be verified in subsequent clinical trials.
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